A new paper titled “Inflammatory vaginitis in women with multiple sclerosis: a retrospective analysis of B-cell depleting therapy compared to other disease modifying therapies” was published in Multiple Sclerosis and Related Disorders by authors Sarah Esther Conway, Cory Dodson, Gavin Hui, C. William Pike and Kristin Galetta. Sarah Esther Conway, MD is affiliated with Brigham and Women’s Hospital and specializes in Neurology in Boston, MA. Dr. Pike and Dr. Hui are affiliated with Atropos Health.
Short Summary:
This study investigates the occurrence of inflammatory vaginitis in women with Multiple Sclerosis (wwMS) undergoing B-cell depleting therapy versus other disease modifying therapies (DMTs). Retrospective analysis of medical records from Stanford University between 2015–2023 shows similar rates of vaginitis in both groups, suggesting no significant association with B-cell therapy. Despite this, inflammatory vaginitis remains prevalent in both treatment groups, warranting further investigation into its mechanisms and management.
Key Conclusions:
- Despite several case reports suggesting so, the authors demonstrate that major B cell therapies used for Multiple Sclerosis (e.g. rituximab, ocrelizumab, ofatumumab) do not increase the risk of vaginitis in women with MS.
Read the full paper here
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com